|
| Press Releases |
|
 |
|
| Monday, August 25, 2025 |
|
|
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. more info >> |
|
| Monday, August 18, 2025 |
|
|
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R) (brand name in China: "DAYVIGO(R)" generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Thursday, July 31, 2025 |
|
|
Revenue of LEQEMBI(R) (Preliminary Basis) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI(R)" (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 - June 30, 2025). more info >> |
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada, and virtually more info >> |
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,"Biogen") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually. more info >> |
|
|
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI(R)), an anti-AB protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually more info >> |
|
| Tuesday, July 29, 2025 |
|
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its in-house discovered tyrosine kinase inhibitor, "LENVIMA(R)" (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma. more info >> |
|
| Friday, July 25, 2025 |
|
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. more info >> |
|
| Wednesday, July 23, 2025 |
|
|
Launch of Beova(R) Tablets in Thailand for Overactive Bladder |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, "KYORIN") announced today that Eisai (Thailand) Marketing Co., Ltd. ("Eisai Thailand"), a subsidiary of Eisai, has launched overactive bladder treatment Beova(R) Tablets (generic name vibegron) in Thailand more info >> |
|
| Tuesday, July 22, 2025 |
|
|
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB;) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI(R)), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27-31. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST
|
|
|
Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST
|
|
|
Asia's Protein Buyers Still Trail Global Best Practice -- But Momentum is Building, New ARE Benchmark Finds
Feb 19, 2026 11:02 HKT/SGT
|
|
|
CDAO Sydney 2026 Announces Two-Day, Co Located Event Series Uniting Australia's Senior Data & AI Leaders
Feb 18, 2026 17:17 HKT/SGT
|
|
|
India's Power Transition Creates Clear Utility Divide
Feb 18, 2026 16:00 HKT/SGT
|
|
|
MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST
|
|
|
IDC MarketScape names Hitachi Energy a Leader in Asset Performance Management for Worldwide Utilities
Feb 18, 2026 10:51 JST
|
|
|
Fujitsu named to FORTUNE Magazine's list of 'World's Most Admired Companie's for eighth year running
Feb 18, 2026 10:41 JST
|
|
|
Kraft Heinz, Braskem, and Tenaris to headline OMP Conference Sao Paulo 2026
Feb 17, 2026 22:00 HKT/SGT
|
|
|
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
Feb 17, 2026 21:00 HKT/SGT
|
|
|
Austral Gold Announces A$8.456 million Strategic Placement
Feb 17, 2026 20:29 HKT/SGT
|
|
|
Supported by U.S. Polo Assn., the 2026 U.S. Open Women's Polo Championship(R) Concludes with Victory Eastern Hay the Champion
Feb 17, 2026 20:00 HKT/SGT
|
|
|
Fujitsu automates entire software development lifecycle with new AI-Driven Software Development Platform
Feb 17, 2026 12:21 JST
|
|
|
Anson Resources to Commence Drilling at Yellow Cat Uranium-Vanadium Project, Utah USA
Feb 17, 2026 07:00 HKT/SGT
|
|
|
Snow master Evans leads 1-2-3-4 finish for TGR-WRT
Feb 16, 2026 15:24 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
